Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01493726 · ClinicalTrials.gov registry record · Phase 1
A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia
A Phase 1 study of Schizophrenia, sponsored by Alkermes.
- Completed
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
- 6
- Study locations
NCT01493726: Completed Phase 1 study of Schizophrenia, sponsored by Alkermes.
NCT01493726 is a Phase 1 study of Schizophrenia that has completed, run by Alkermes. The registered enrollment target is 88 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (60% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01493726, a Phase 1 study of Schizophrenia, has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study will determine the pharmacokinetics (PK), safety, and tolerability of ALKS 9072 (also known as ALKS 9070) after 4 monthly doses in adults with chronic stable schizophrenia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ALKS 9072, Low dose
- DRUG ALKS 9072, Med dose
- DRUG ALKS 9072, High dose
Study Locations (6)
Georgia
- Alkermes Investigational Site - Atlanta
Illinois
- Alkermes Investigational Site - Hoffman Estates
Missouri
- Alkermes Investigational Site - St Louis
New Jersey
- Alkermes Investigational Site - Willingboro
Pennsylvania
- Alkermes Investigational Site - Philadelphia
Texas
- Alkermes Investigational Site - Irving
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
What the finished NCT01493726 record still lists
NCT01493726 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT01493726 lists 6 locations in 6 states (Georgia, Illinois, Missouri).
Frequently Asked Questions
What is clinical trial NCT01493726 about?
NCT01493726 is a clinical study titled "A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia". This study will determine the pharmacokinetics (PK), safety, and tolerability of ALKS 9072 (also known as ALKS 9070) after 4 monthly doses in adults with chronic stable schizophrenia.
What is the current status of trial NCT01493726?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2011-12. Estimated completion is 2013-06.
What conditions does trial NCT01493726 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT01493726?
The interventions under investigation include: Placebo (DRUG), ALKS 9072, Low dose (DRUG), ALKS 9072, Med dose (DRUG), ALKS 9072, High dose (DRUG).
Who is sponsoring clinical trial NCT01493726?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01493726 being conducted?
This trial has 6 study locations across Georgia, Illinois, Missouri, New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01493726's enrollment target sits among peer trials
88 153rd of 315 higher than 162 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Imaging Synapses With [11C] UCB-J in the Human Brain
RECRUITING · Phase 1
-
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
RECRUITING · Phase 1
-
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
RECRUITING · Phase 1
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RECRUITING · Phase 1
-
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia